Corgenix Med Corp (CONX) 0.2592 $CONX
Corgenix Medical Corporation Stockholders Encouraged to Contact Securities Law Firm about the definitive merger agreement to be acquired by Orgentec Diagnostika
PR Newswire - Wed Sep 03, 4:52PM CDT
Securities lawyers at Dunnam & Dunnam are investigating potential claims against the Board of Directors of Corgenix Medical Corporation (OTC:CONX) in connection with the definitive merger agreement of Corgenix Medical to Orgentec Diagnostika. Concerned CONX investors are encouraged to contact attorney Hamilton Lindley by clicking here.
Corgenix to be acquired by Orgentec Diagnostika in USD16m transaction
M2 - Fri Aug 29, 6:32AM CDT
Corgenix Medical Corporation (OTCQB:CONX.OB), a developer and marketer of diagnostic test kits, announced on Thursday the entering into a definitive merger agreement to be acquired by Orgentec Diagnostika, a specialty diagnostics company headquartered in Mainz, Germany.
Corgenix Provides Update on Ebola Test Kit NIH Grant
Business Wire - Mon Aug 11, 8:15AM CDT
Ebola virus outbreaks tend to occur every few years and then go away rapidly. However, this year's outbreak is the worst in recorded history, with the total number of deaths approaching 1,000. As reported previously, Corgenix Medical Corporation (OTCBB:CONX), a worldwide developer and marketer of diagnostic test kits, commenced work on a $2.9 million National Institutes of Health (NIH) grant in June.
Corgenix Rapid Diagnostic Ebola Test Research Earns Divisional Best Abstract Award at AACC 2014 Meeting
Business Wire - Wed Jul 30, 8:15AM CDT
Corgenix Medical Corporation (OTCBB: CONX) has been recognized for outstanding research presented today at the American Association for Clinical Chemistry (AACC) Annual Meeting and Clinical Lab Expo 2014 in Chicago. Corgenix earned the award for its poster abstract "Development of a Point-of-Care Diagnostic for Ebola and Sudan Virus Detection," presented at the conference by Corgenix Research Associate Abby Jones, M.S.
Corgenix Joins Strategic Partners, Presents Science at AACC Meeting and Clinical Lab Expo 2014
Business Wire - Tue Jul 22, 8:15AM CDT
Corgenix Medical Corporation (OTC BB: CONX.OB), a worldwide developer and marketer of diagnostic test kits, will collaborate with strategic partners and also present several scientific abstracts at the American Association for Clinical Chemistry (AACC) Annual Meeting and Clinical Lab Expo 2014 in Chicago.
Corgenix enters into technology transfer & product development agreement for Mellitussfor gestational diabetes test GCD59
M2 - Tue Jul 15, 8:29AM CDT
Diagnostic test kits company Corgenix Medical (Other OTC:CONX) on Monday launched a technology transfer and product development agreement with Mellitus in support of clinical research and product commercialisation.
Corgenix Signs Technology Transfer, Product Development Agreement with Mellitus LLC for Gestational Diabetes Test
Business Wire - Mon Jul 14, 8:15AM CDT
Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, today announced a technology transfer and product development agreement with Mellitus LLC of Cambridge, Mass. Mellitus is a private company that is developing a novel in vitro diagnostic test with potential clinical utility for diabetes. The test is based on the measurement of Glycated CD59 (GCD59.)
Corgenix, Research Group Announce NIH Grant to Advance Work on Ebola Rapid Diagnostic Test Kit
Business Wire - Thu Jun 26, 8:15AM CDT
Corgenix Medical Corporation (OTC BB: CONX.OB), a worldwide developer and marketer of diagnostic test kits, has been awarded a three-year, $2.9 million National Institutes of Health (NIH) grant to advance the development of an Ebola rapid diagnostic test kit. Collaborating with Corgenix on the program will be members of the Viral Hemorrhagic Fever Consortium (VHFC), a collaboration of academic and industry members headed by Tulane University and partially funded with support from the NIH.
Corgenix, Tulane and Viral Hemorrhagic Fever Consortium Publish Promising Results from Lassa Fever Trial
Business Wire - Tue Apr 01, 8:15AM CDT
A Corgenix Medical (OTCBB:CONX) rapid diagnostic test (RDT) for the dangerous Lassa fever virus has demonstrated the ability to quickly detect the virus, responsible for the deaths of thousands and infection of hundreds of thousands in West Africa each year. That's according to the results of the five-year trial Lassa Fever in Post-Conflict Sierra Leone published in the PLOS Neglected Tropical Diseases Journal.
Corgenix and Research Partners to Expand Ebola Virus Testing Capabilities in Sierra Leone
Business Wire - Thu Mar 27, 8:15AM CDT
An outbreak of the deadly Ebola virus in West Africa has prompted Corgenix Medical Corporation (OTCBB:CONX) to extend its existing viral hemorrhagic fever (VHF) rapid test development to include the Ebola virus. Corgenix has already developed and CE marked a rapid test for the Lassa fever virus, another member of the VHF group of viruses.
Corgenix Board of Directors Announces Exploration of Strategic Alternatives
Business Wire - Wed Mar 12, 8:15AM CDT
Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, announced today that the Company's Board of Directors has decided to explore strategic alternatives to enhance value for shareholders. These alternatives could include, among others, possible joint ventures, strategic partnerships or alliances, a sale of the Company or other possible transactions.
Corgenix Medical Corporation posts higher net income of USD178,497 for Q2 fiscal 2014
M2 - Fri Feb 14, 3:06AM CST
Diagnostic test kits company Corgenix Medical Corporation (OTC BB:CONX) reported on Thursday its net income of USD178,497 for second quarter fiscal 2014.
Corgenix Reports Second Quarter Fiscal 2014 Financial Results
Business Wire - Thu Feb 13, 8:15AM CST
Corgenix Medical Corporation (OTC BB: CONX), a worldwide developer and marketer of diagnostic test kits, today filed its second quarter Form 10-Q and reported its financial results. The report disclosed that the company's revenues and net income increased both for the quarter and year to date. Some of the results highlighted by the report are as follows:
Corgenix to Host Conference Call to Discuss Second Quarter Results
Business Wire - Tue Feb 04, 8:15AM CST
Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, will host a conference call on Thursday, February 13, 2014, at 4:00 p.m. EST to discuss the Company's financial and operating performance for its quarter ended December 31, 2013, and the status of the Company's product development and marketing activities.
Corgenix to Host Conference Call to Discuss Fiscal 2013 Results
Business Wire - Wed Sep 18, 8:15AM CDT
Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, will host a conference call on Monday, September 30, 2013, at 4:00 PM EDT to discuss the Company's financial and operating performance for its fiscal year ended June 30, 2013, and the status of the Company's product development and marketing activities.
Corgenix Medical Corporation renews agreement with Dr Matsuura and retains right to the AtherOx technology
M2 - Wed Sep 11, 9:38AM CDT
Diagnostic kits company Corgenix Medical Corporation (OTCQB:CONX.OB) reported on Tuesday the execution of a new AtherOx License and Cooperation Agreement with Dr Eiji Matsuura of Okayama, Japan.
Corgenix Medical Corporation Announces New AtherOx(R) (Oxidized LDL Technology) License and Cooperation Agreement
Business Wire - Tue Sep 10, 8:15AM CDT
Corgenix Medical Corporation (OTCQB: CONX.OB), a worldwide developer and marketer of diagnostic test kits, today announced signing of a new AtherOx(R) License and Cooperation Agreement with Eiji Matsuura, Ph.D., an individual of Okayama, Japan. Concurrently with the execution of the new agreement, Dr. Matsuura terminated his arbitration demand of June 28, 2013 related to the April 14, 2010 Amended and Restated License Agreement between the parties.
Corgenix Medical Corporation reports new USD1.5m revolving credit facility, with favorable interest rate and greater flexibility
M2 - Thu Sep 05, 6:29AM CDT
Diagnostic test kits company Corgenix Medical Corporation (OTCQB:CONX.OB) revealed on Wednesday the completion of a USD1.5m secured revolving line of credit with Bank of the West.
Corgenix Medical Corporation Announces New $1.5 Million Revolving Credit Facility
Business Wire - Wed Sep 04, 8:15AM CDT
Corgenix Medical Corporation (OTCQB: CONX.OB), a worldwide developer and marketer of diagnostic test kits, today announced that it has closed on a $1.5 million secured revolving line of credit with Bank of the West. The new revolving line of credit provides Corgenix a very favorable interest rate and much greater flexibility than the previous asset-based revolving line of credit. The new credit facility follows the recent move by Corgenix of its primary banking arrangements to Bank of the West.
OTC Daily Alert Stock Watch - Corgenix (OTCQB: CONX)
WorldStockWire - Tue Aug 27, 7:15PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Corgenix Medical Corporation Stockholders Encouraged to Contact Securities Law Firm about the definitive merger agreement to be acquired by Orgentec Diagnostika
PR Newswire - Wed Sep 03, 4:52PM CDT
Securities lawyers at Dunnam & Dunnam are investigating potential claims against the Board of Directors of Corgenix Medical Corporation (OTC:CONX) in connection with the definitive merger agreement of Corgenix Medical to Orgentec Diagnostika. Concerned CONX investors are encouraged to contact attorney Hamilton Lindley by clicking here.
Corgenix to be acquired by Orgentec Diagnostika in USD16m transaction
M2 - Fri Aug 29, 6:32AM CDT
Corgenix Medical Corporation (OTCQB:CONX.OB), a developer and marketer of diagnostic test kits, announced on Thursday the entering into a definitive merger agreement to be acquired by Orgentec Diagnostika, a specialty diagnostics company headquartered in Mainz, Germany.
Corgenix Provides Update on Ebola Test Kit NIH Grant
Business Wire - Mon Aug 11, 8:15AM CDT
Ebola virus outbreaks tend to occur every few years and then go away rapidly. However, this year's outbreak is the worst in recorded history, with the total number of deaths approaching 1,000. As reported previously, Corgenix Medical Corporation (OTCBB:CONX), a worldwide developer and marketer of diagnostic test kits, commenced work on a $2.9 million National Institutes of Health (NIH) grant in June.
Corgenix Rapid Diagnostic Ebola Test Research Earns Divisional Best Abstract Award at AACC 2014 Meeting
Business Wire - Wed Jul 30, 8:15AM CDT
Corgenix Medical Corporation (OTCBB: CONX) has been recognized for outstanding research presented today at the American Association for Clinical Chemistry (AACC) Annual Meeting and Clinical Lab Expo 2014 in Chicago. Corgenix earned the award for its poster abstract "Development of a Point-of-Care Diagnostic for Ebola and Sudan Virus Detection," presented at the conference by Corgenix Research Associate Abby Jones, M.S.
Corgenix Joins Strategic Partners, Presents Science at AACC Meeting and Clinical Lab Expo 2014
Business Wire - Tue Jul 22, 8:15AM CDT
Corgenix Medical Corporation (OTC BB: CONX.OB), a worldwide developer and marketer of diagnostic test kits, will collaborate with strategic partners and also present several scientific abstracts at the American Association for Clinical Chemistry (AACC) Annual Meeting and Clinical Lab Expo 2014 in Chicago.
Corgenix enters into technology transfer & product development agreement for Mellitussfor gestational diabetes test GCD59
M2 - Tue Jul 15, 8:29AM CDT
Diagnostic test kits company Corgenix Medical (Other OTC:CONX) on Monday launched a technology transfer and product development agreement with Mellitus in support of clinical research and product commercialisation.
Corgenix Signs Technology Transfer, Product Development Agreement with Mellitus LLC for Gestational Diabetes Test
Business Wire - Mon Jul 14, 8:15AM CDT
Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, today announced a technology transfer and product development agreement with Mellitus LLC of Cambridge, Mass. Mellitus is a private company that is developing a novel in vitro diagnostic test with potential clinical utility for diabetes. The test is based on the measurement of Glycated CD59 (GCD59.)
Corgenix, Research Group Announce NIH Grant to Advance Work on Ebola Rapid Diagnostic Test Kit
Business Wire - Thu Jun 26, 8:15AM CDT
Corgenix Medical Corporation (OTC BB: CONX.OB), a worldwide developer and marketer of diagnostic test kits, has been awarded a three-year, $2.9 million National Institutes of Health (NIH) grant to advance the development of an Ebola rapid diagnostic test kit. Collaborating with Corgenix on the program will be members of the Viral Hemorrhagic Fever Consortium (VHFC), a collaboration of academic and industry members headed by Tulane University and partially funded with support from the NIH.
Corgenix, Tulane and Viral Hemorrhagic Fever Consortium Publish Promising Results from Lassa Fever Trial
Business Wire - Tue Apr 01, 8:15AM CDT
A Corgenix Medical (OTCBB:CONX) rapid diagnostic test (RDT) for the dangerous Lassa fever virus has demonstrated the ability to quickly detect the virus, responsible for the deaths of thousands and infection of hundreds of thousands in West Africa each year. That's according to the results of the five-year trial Lassa Fever in Post-Conflict Sierra Leone published in the PLOS Neglected Tropical Diseases Journal.
Corgenix and Research Partners to Expand Ebola Virus Testing Capabilities in Sierra Leone
Business Wire - Thu Mar 27, 8:15AM CDT
An outbreak of the deadly Ebola virus in West Africa has prompted Corgenix Medical Corporation (OTCBB:CONX) to extend its existing viral hemorrhagic fever (VHF) rapid test development to include the Ebola virus. Corgenix has already developed and CE marked a rapid test for the Lassa fever virus, another member of the VHF group of viruses.
Corgenix Board of Directors Announces Exploration of Strategic Alternatives
Business Wire - Wed Mar 12, 8:15AM CDT
Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, announced today that the Company's Board of Directors has decided to explore strategic alternatives to enhance value for shareholders. These alternatives could include, among others, possible joint ventures, strategic partnerships or alliances, a sale of the Company or other possible transactions.
Corgenix Medical Corporation posts higher net income of USD178,497 for Q2 fiscal 2014
M2 - Fri Feb 14, 3:06AM CST
Diagnostic test kits company Corgenix Medical Corporation (OTC BB:CONX) reported on Thursday its net income of USD178,497 for second quarter fiscal 2014.
Corgenix Reports Second Quarter Fiscal 2014 Financial Results
Business Wire - Thu Feb 13, 8:15AM CST
Corgenix Medical Corporation (OTC BB: CONX), a worldwide developer and marketer of diagnostic test kits, today filed its second quarter Form 10-Q and reported its financial results. The report disclosed that the company's revenues and net income increased both for the quarter and year to date. Some of the results highlighted by the report are as follows:
Corgenix to Host Conference Call to Discuss Second Quarter Results
Business Wire - Tue Feb 04, 8:15AM CST
Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, will host a conference call on Thursday, February 13, 2014, at 4:00 p.m. EST to discuss the Company's financial and operating performance for its quarter ended December 31, 2013, and the status of the Company's product development and marketing activities.
Corgenix to Host Conference Call to Discuss Fiscal 2013 Results
Business Wire - Wed Sep 18, 8:15AM CDT
Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, will host a conference call on Monday, September 30, 2013, at 4:00 PM EDT to discuss the Company's financial and operating performance for its fiscal year ended June 30, 2013, and the status of the Company's product development and marketing activities.
Corgenix Medical Corporation renews agreement with Dr Matsuura and retains right to the AtherOx technology
M2 - Wed Sep 11, 9:38AM CDT
Diagnostic kits company Corgenix Medical Corporation (OTCQB:CONX.OB) reported on Tuesday the execution of a new AtherOx License and Cooperation Agreement with Dr Eiji Matsuura of Okayama, Japan.
Corgenix Medical Corporation Announces New AtherOx(R) (Oxidized LDL Technology) License and Cooperation Agreement
Business Wire - Tue Sep 10, 8:15AM CDT
Corgenix Medical Corporation (OTCQB: CONX.OB), a worldwide developer and marketer of diagnostic test kits, today announced signing of a new AtherOx(R) License and Cooperation Agreement with Eiji Matsuura, Ph.D., an individual of Okayama, Japan. Concurrently with the execution of the new agreement, Dr. Matsuura terminated his arbitration demand of June 28, 2013 related to the April 14, 2010 Amended and Restated License Agreement between the parties.
Corgenix Medical Corporation reports new USD1.5m revolving credit facility, with favorable interest rate and greater flexibility
M2 - Thu Sep 05, 6:29AM CDT
Diagnostic test kits company Corgenix Medical Corporation (OTCQB:CONX.OB) revealed on Wednesday the completion of a USD1.5m secured revolving line of credit with Bank of the West.
Corgenix Medical Corporation Announces New $1.5 Million Revolving Credit Facility
Business Wire - Wed Sep 04, 8:15AM CDT
Corgenix Medical Corporation (OTCQB: CONX.OB), a worldwide developer and marketer of diagnostic test kits, today announced that it has closed on a $1.5 million secured revolving line of credit with Bank of the West. The new revolving line of credit provides Corgenix a very favorable interest rate and much greater flexibility than the previous asset-based revolving line of credit. The new credit facility follows the recent move by Corgenix of its primary banking arrangements to Bank of the West.
OTC Daily Alert Stock Watch - Corgenix (OTCQB: CONX)
WorldStockWire - Tue Aug 27, 7:15PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
